SS-31 moved to Approved Pharma on accelerated approval for Barth syndrome

Arkham Labs editorial/Published 12 September 2026/Corrections policy

The grade records the marketing authorisation and nothing beyond it. Approval for one rare indication is not evidence for any other use, and SS-31 is discussed in a great many contexts that have nothing to do with Barth syndrome. The guide names the indication in the grade line for exactly that reason.

Grade changed

Grade changed.

Guides affected by this note: SS-31.

Field notes record what changed in the library. Where the effect on a grade is none, that is stated rather than omitted — a note saying nothing changed is the same evidence as a note saying something did.

All field notes →How grading works

Standing notice

For laboratory research use only. Not for human consumption. Nothing here is medical advice.

ArkhamLabs

An independent peptide-science review. It sells no products and earns referral revenue from two disclosed commercial relationships.

Publication

Compound library Families Sourcing and quality Field notes

Accountability

Editorial standards Commercial disclosure

The grading rule

Four grades, applied uniformly: Preclinical, Early Clinical, Approved Pharma, Mixed Evidence. The grade reflects the state of the literature, not an opinion on whether a compound works.

For laboratory research use only. Not for human consumption. Nothing here is medical advice.
© 2026 Arkham Labs · arkhamlabs.co